NASDAQ · ITOS
Healthcare · Biotechnology
$10.15
Up+$0.02 (+0.20%)
Updated Aug 16, 2026, 8:04 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ITOS does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ITOS.
ITOS research
Company profile and research snapshot.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2025 | Wells Fargo | Equal-Weight | — |
| May 28, 2025 | Wells Fargo | Equal-Weight | — |
| May 28, 2025 | Wedbush | Neutral | — |
| May 14, 2025 | Piper Sandler | Overweight | — |
| May 14, 2025 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jul 26, 2025
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies, including iTeos Therapeutics, City Office REIT, and Synovus Financial Corp, focusing on recent merger and acquisition transactions.
GlobeNewswire Inc. · Jul 21, 2025
Law firm Monteverde & Associates is investigating the proposed acquisition of iTeos Therapeutics by Concentra Biosciences, offering $10.047 per share plus contingent value rights.
Benzinga · Jul 21, 2025
iTeos Therapeutics has agreed to be acquired by Concentra Biosciences for $10.047 in cash per share, plus a contingent value right. The transaction is expected to close in Q3 2025, subject to customary closing conditions and stockholder approval.
GlobeNewswire Inc. · Apr 29, 2025
iTeos Therapeutics reported financial results for Q1 2025 and provided updates on its clinical programs, including upcoming data readouts for its TIGIT and adenosine inhibitor candidates.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ITOS.
No results
No recent SID articles mention ITOS.
